Verification: db19c6b9c173df77
Логотип Ретатрутид (Retatrutide Triple Agonist)

Retatrutide Protocols

Retatrutide (LY3437943)Triple Agonist

Clinical guideline, titration schedule, dosages, and side effect management for obesity and T2D

\
Ad

Advertising in preparation

Account: your health data stays in your browserGDPR / Privacy

Questionnaire and diary are encrypted with your password and stored only in this browser. The site owner does not receive them.

Body Weight & Titration Diary

Weight Loss Trajectory Tracker

Log daily or weekly weigh-ins to monitor fat loss rate during triple agonist Retatrutide (GIP/GLP-1/GCG) therapy.

Stored in this browser. Log in to encrypt with your password.
Current Weight
88kg
Start:102.5 kg
Total Lost
-14.5kg-14.1%
Rate: ~1.04 kg/wk
Goal: 80 kg
8kg left
Progress64%
Body Mass Index (BMI)
28.7kg/m²↓ 4.8
Overweight (Pre-obesity)

Weight Loss Dynamics & Weekly Progress

Recharts visualization: absolute weight, weekly fat loss rate, and dosage titration

Time Range:
Apr 01Apr 08Apr 15Apr 22Apr 29May 06May 13May 20May 27Jun 03Jun 10Jun 17Jun 24Jul 01Jul 0886 kg91 kg96 kg101 kg104.5 kg
Actual weight
Moving average
Goal target (80 kg)
*Interactive Recharts analytics

Add New Weigh-in Record

kg
Weighing Best Practices
  • Morning Standard: Weigh on an empty stomach, after using the restroom, at the same time each day.
  • Fluctuation Norms: Daily weight may fluctuate ±1.5 kg due to fluid retention, salt, or hydration. Evaluate smoothed trend line!
  • Retatrutide Efficacy: In TRIUMPH-1 trial, mean weight loss reached -28.3% at 80 weeks (and -30.3% at 104 weeks in the extension) on 12 mg dose.

History Log (15)

No record limit; sorted oldest to newest
DateWeight (kg)BMIChangeRetatrutide DoseWaist (cm)NotesActions
Apr 01, 2026102.5 kg33.5Starttotal: +0 kg2 mg108 cmStarted Retatrutide titration 2 mg
Apr 08, 2026101.2 kg33-1.3 kgtotal: -1.3 kg2 mg107 cmReduced appetite from Day 2
Apr 15, 2026100.1 kg32.7-1.1 kgtotal: -2.4 kg2 mg106 cmEarly satiety
Apr 22, 202699.3 kg32.4-0.8 kgtotal: -3.2 kg2 mg105 cmLost 3.2 kg in first 3 weeks
Apr 29, 202698.4 kg32.1-0.9 kgtotal: -4.1 kg4 mg104 cmIncreased dose to 4 mg
May 06, 202697.2 kg31.7-1.2 kgtotal: -5.3 kg4 mg103 cmMild nausea on day 1 post injection
May 13, 202696.1 kg31.4-1.1 kgtotal: -6.4 kg4 mg102 cmFeeling great, energy expenditure up
May 20, 202695 kg31-1.1 kgtotal: -7.5 kg4 mg101 cmLost 7.5 kg from baseline
May 27, 202694.2 kg30.8-0.8 kgtotal: -8.3 kg4 mg100 cmSteady weight loss
Jun 03, 202693.1 kg30.4-1.1 kgtotal: -9.4 kg8 mg99 cmEscalated to 8 mg maintenance dose
Jun 10, 202691.8 kg30-1.3 kgtotal: -10.7 kg8 mg98 cmEnhanced fat oxidation (triple agonism)
Jun 17, 202690.7 kg29.6-1.1 kgtotal: -11.8 kg8 mg97 cmWaist circumference reduced by 11 cm
Jun 24, 202689.6 kg29.3-1.1 kgtotal: -12.9 kg8 mg96 cmContinuing therapy
Jul 01, 202688.8 kg29-0.8 kgtotal: -13.7 kg8 mg95 cmMaintaining strong trajectory
Jul 08, 202688 kg28.7-0.8 kgtotal: -14.5 kg8 mg94 cmCurrent total: -14.5 kg (-14.1%)

Weight & Health Metrics: glucose, uric acid, cholesterol, blood pressure

One table, no record limit. Weight entered here also goes to the weight diary. After login the data is stored on the server and deleted together with the profile.

Glucose, mmol/L
  • Glucose
  • Weight, kg (right axis)
Apr 15, 26May 06, 26May 27, 26Jun 17, 26Jul 08, 26869196101104.5
Uric acid, µmol/L
  • Uric acid
  • Weight, kg (right axis)
Apr 15, 26May 06, 26May 27, 26Jun 17, 26Jul 08, 26869196101104.5
Cholesterol, mmol/L
  • LDL
  • Total cholesterol
  • Weight, kg (right axis)
Apr 15, 26May 06, 26May 27, 26Jun 17, 26Jul 08, 26869196101104.5
Blood pressure, mmHg
  • Diastolic BP
  • Systolic BP
  • Weight, kg (right axis)
Apr 15, 26May 06, 26May 27, 26Jun 17, 26Jul 08, 26869196101104.5
DateWeightGlucoseUric acidTotal cholesterolLDLSystolic BPDiastolic BPNotes
Jul 08, 2688———————
Jul 01, 2688.8———————
Jun 24, 2689.6———————
Jun 17, 2690.7———————
Jun 10, 2691.8———————
Jun 03, 2693.1———————
May 27, 2694.2———————
May 20, 2695———————
May 13, 2696.1———————
May 06, 2697.2———————
Apr 29, 2698.4———————
Apr 22, 2699.3———————
Apr 15, 26100.1———————
Apr 08, 26101.2———————
Apr 01, 26102.5———————

Dashed lines are common reference limits for adults (fasting glucose 5.5, uric acid 360 F / 420 M, total cholesterol 5.2, LDL 3.0, BP 130/80). For information only; targets are set by your doctor.

Reference application for Retatrutide (LY3437943) administration protocols. Developed based on published clinical trial data from TRIUMPH and TRANSCEND (Eli Lilly, NEJM, Lancet 2023–2026).

ATTENTION! MEDICAL DISCLAIMER & TERMS OF USE:

All information provided on this website is a creative synthesis of results from specified scientific research. The administration accepts no liability for any inaccuracies or errors and reminds users that this resource should only be used under qualified medical supervision.

Only a qualified physician can diagnose and prescribe medical treatment.

LEGAL STATUS OF CONTENT & USAGE RESTRICTIONS:

All materials published on retatrutid.ru, including descriptions, visual elements, data structure, code, design, domain name, and project branding, are protected intellectual property objects under applicable laws and international copyright conventions.

Direct or indirect copying, reproduction, distribution, or republication of content without prior written consent from the copyright holder is strictly prohibited.

retatrutid.ru • Official Legal Terms
©Rid_Streenger 2026ИП Алексеенков Дмитрий Петрович · ИНН 781128861076
Cookie Usage & Privacy NoticeGDPR / Privacy

We use essential cookies to ensure secure authentication, save filled medical questionnaires (height, weight, age, glucose), and operate calculators correctly. Optional cookies help optimize performance.